SAREPTA THERAPEUTICS, INC. Fair Value Adjustment of Warrants
SAREPTA THERAPEUTICS, INC. (SRPT) reported Fair Value Adjustment of Warrants of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2017-02-28
- SAREPTA THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2014-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2014-09-30 was -$4.26M, a 124.80% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2014-06-30 was $3.78M, a 94.55% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2014-03-31 was $3.25M, a 87.92% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2016 was $0.00.
- SAREPTA THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- SAREPTA THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2014 was $2.78M, a 87.38% decline from fiscal 2013.
- SAREPTA THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2013 was $22.03M, a 76.04% decline from fiscal 2012.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 395 month | Fair Value Adjustment of Warrants 398 month | Fair Value Adjustment of Warrants 401 month | Fair Value Adjustment of Warrants 404 month |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-28 | |||||||
| 2015-12-31 | $0.00 10-K · filed 2017-02-28 | |||||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$4.26M derived: sum of 2 quarters · filed 2017-02-28 | -$472.00K derived: sum of 3 quarters · filed 2017-02-28 | $2.78M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | -$4.26M 10-K · filed 2016-02-25 | -$472.00K derived: sum of 2 quarters · filed 2016-02-25 | $2.78M 10-Q · filed 2015-11-05 | -$21.20M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $3.78M 10-K · filed 2016-02-25 | $7.04M 10-Q · filed 2015-08-06 | -$16.95M derived: sum of 3 quarters · filed 2016-02-25 | $211.00K derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $3.25M 10-K · filed 2016-02-25 | -$20.73M derived: sum of 2 quarters · filed 2016-02-25 | -$3.57M derived: sum of 3 quarters · filed 2016-02-25 | -$1.63M derived: sum of 4 quarters · filed 2016-02-25 | $92.25M 10-Q · filed 2014-05-08 | |||
| 2013-12-31 | -$23.98M 10-K · filed 2015-02-26 | -$6.82M derived: sum of 2 quarters · filed 2015-02-26 | -$4.88M derived: sum of 3 quarters · filed 2015-02-26 | $22.03M 10-K · filed 2016-02-25 | $89.00M 10-K · filed 2014-03-03 | |||
| 2013-09-30 | $17.16M 10-Q · filed 2014-11-06 | $19.11M derived: sum of 2 quarters · filed 2015-02-26 | $46.01M 10-Q · filed 2014-11-06 | $97.80M derived: sum of 4 quarters · filed 2015-02-26 | $112.98M 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $1.95M 10-K · filed 2015-02-26 | $28.85M 10-Q · filed 2014-08-07 | $80.64M derived: sum of 3 quarters · filed 2015-02-26 | $123.35M derived: sum of 4 quarters · filed 2015-02-26 | $95.82M 10-Q · filed 2013-08-08 | |||
| 2013-03-31 | $26.91M 10-K · filed 2015-02-26 | $78.69M derived: sum of 2 quarters · filed 2015-02-26 | $121.41M derived: sum of 3 quarters · filed 2015-02-26 | $107.92M derived: sum of 4 quarters · filed 2015-02-26 | ||||
| 2012-12-31 | $51.78M 10-K · filed 2014-03-03 | $94.50M derived: sum of 2 quarters · filed 2014-03-03 | $81.01M derived: sum of 3 quarters · filed 2014-03-03 | $91.94M 10-K · filed 2015-02-26 | ||||
| 2012-09-30 | $42.72M 10-K · filed 2014-03-03 | $29.23M derived: sum of 2 quarters · filed 2014-03-03 | $40.15M 10-Q · filed 2013-11-12 | |||||
| 2012-06-30 | -$13.49M 10-K · filed 2014-03-03 | -$2.56M 10-Q · filed 2013-08-08 | ||||||
| 2012-03-31 | $10.93M 10-K · filed 2014-03-03 | |||||||
| 2011-12-31 | -$33.02M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |